<?xml version="1.0" encoding="UTF-8"?>
<p id="p0235">Favipiravir was approved for treatment of influenza on February 15, 2020, in China and is being studied in COVID-19 clinical trials. The preliminary results indicate that favipiravir has significantly more potent antiviral action and fewer adverse effects than lopinavir/ritonavir (
 <italic>P</italic> &lt; 0.001).
 <xref rid="bib42" ref-type="bibr">
  <sup>42</sup>
 </xref> One of the clinical trials was conducted in Shenzhen, and the results showed that the median time to viral clearance was 4 days in the favipiravir treatment group compared with 11 days in the lopinavir/ritonavir treatment group (
 <italic>P</italic> &lt; 0.001). In terms of chest imaging, the improvement rates of the favipiravir treatment group and the lopinavir/ritonavir treatment group were 91.4% and 62.2%, respectively. No significant adverse reactions were noted in the favipiravir treatment group, and there were significantly fewer adverse effects than in the lopinavir/ritonavir group.
 <xref rid="bib43" ref-type="bibr">
  <sup>43</sup>
 </xref>
</p>
